This report describes the production of ERM®-AD455k/IFCC, which is a material certified for the catalytic activity concentration of creatine kinase (CK). This material was produced in collaboration with the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) following...

This report describes the production of ERM®-AD454k/IFCC, which is a material certified for the catalytic activity concentration of alanine aminotransferase (ALT). This material was produced in collaboration with the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC)...

This report describes the production of ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC, which are human cerebrospinal fluid (CSF) materials certified for the mass concentration of amyloid β1-42 peptide (Aβ1-42). These materials were produced by the European Commission's Joint Research...

This report describes the production and certification of ERM-DA483/IFCC, a serum protein reference material intended for the standardisation of measurements of immunoglobulin G proteinase 3 anti-neutrophil cytoplasmic autoantibodies (IgG PR3 ANCA). The material was produced according to ISO...

This report describes the additional certification of the mass concentration of beta-2-microglobulin (B2M) in ERM-DA470k/IFCC, a human serum material. The material was released in 2008 and was certified for the mass concentration of 12 proteins in human serum. The material is now additionally...

This report describes the production of ERM-AD500/IFCC, which is a set of 6 ampoules containing haemoglobin (with different levels of HbA1c) in a buffer solution, certified for the amount-of-substance fraction of HbA1c versus the sum of HbA0 and HbA1c. HbA1c is defined as the stable adduct from...

This report describes the production and certification of ERM-DA476/IFCC, a new serum protein reference material intended for the standardisation of measurements of anti-myeloperoxidase immunoglobulin G (anti-MPO IgG) antibodies. The material was produced according to ISO Guide 34:2009 . The raw...

Antimicrobial Resistance (AMR) represents a serious global health threat, which was directly responsible for almost 1.2 million deaths worldwide in 2021 and contributed to another 4.7 million deaths the same year. It is estimated that there could be over 8.2 million deaths linked to resistant...

Phage therapy, used as alternative or in synergy with antibiotics, has the potential to help combat the global threat of antimicrobial resistance. However, due to the nature of this therapy, the current marketing authorisation procedure for medicinal products does not fully comply with the needs...